Mitral Valve Replacement in Pediatrics Using an Extracellular Matrix Cylinder Valve: A Case Series
- PDF / 974,722 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 10 Downloads / 214 Views
ORIGINAL ARTICLE
Mitral Valve Replacement in Pediatrics Using an Extracellular Matrix Cylinder Valve: A Case Series Carmen Kiper1 · Clifford L. Cua1 · Peter Baker III2 · Patrick McConnell3 Received: 1 April 2020 / Accepted: 22 May 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Mitral valve replacement (MVR) in children under 2 years is associated with significant morbidity and mortality. Decellularized porcine intestinal submucosa is a commercially available formulation of an extracellular matrix (ECM) with an indication for cardiac tissue repair. The present study reports our experience using ECM cylinder valves in patients for MVR. A retrospective review of patients under 2 years who underwent ECM custom-made cylinder mitral valve (ECM-MV) replacement was performed. Clinical, demographic, operative and post-operative follow-up data, including serial echocardiographic data are presented. Eight patients (age 5.6 ± 1.6 months; weight: 6.0 ± 1.1 kg) were identified who underwent ECM-MVR. There was one in-hospital death and no major neurological events. Six patients underwent replacement of their cylinder valve with either a Melody valve inside the ECM-MVR (n = 3), a mechanical valve (n = 2), or a decellularized bovine pericardial cylinder valve (n = 1). The mean time to replacement surgery was 8.4 ± 2.6 months after ECM-MV. The indications for replacement of ECM-MV included mitral stenosis/regurgitation (n = 4) or dehiscence (n = 2). One remaining patient is 24 months from ECM-MV, with trivial regurgitation and no stenosis. Mitral valve creation using ECM is an option for MVR in pediatrics, avoiding anticoagulation, and provides a suitable construct for later placement of a Melody valve, extending surgical and non-surgical options. However, the durability of the native ECM-MV in the mitral position is concerning considering the high re-intervention rate in a relatively short time period. Further studies are needed to determine the longer-term outcomes of this valve in this complex patient population. Keywords Mitral valve replacement · Mitral stenosis · Mitral regurgitation · Cormatrix
Introduction Mitral valve (MV) replacement in the pediatric population has significant morbidity and mortality, especially in patients under 1 year [1, 2], due to issues of valve sizing, durability, growth and anticoagulation [3]. Options include surgical placement of small commercially available bioprosthetic or mechanical valves, or surgical placement of modified transcatheter bioprosthetic valves, such as the Melody valve (Medtronic, Minneapolis, MN) [4]. Each valve replacement * Carmen Kiper [email protected] 1
Department of Pediatrics, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205, USA
2
Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USA
3
Department of Cardiothoracic Surgery, Nationwide Children’s Hospital, Columbus, OH 43205, USA
option has its own set of advantages and disa
Data Loading...
